Rohto Pharmaceutical Co ( (JP:4527) ) has provided an update.
Rohto Pharmaceutical reported significant sales growth in Q3 of FY 2025, driven by increased inbound demand and currency effects from yen depreciation. Despite the growth in sales, profits decreased due to higher costs of sales and increased R&D and administrative expenses. The company experienced strong performance in its domestic market and a double-digit sales increase in the Americas, Europe, and Asia. The year-end dividend is set to increase, marking 21 consecutive years of dividend growth.
More about Rohto Pharmaceutical Co
Rohto Pharmaceutical Co., Ltd. is a prominent player in the pharmaceutical industry, offering a range of health and wellness products. The company focuses on consumer needs with products including lip balms, supplements, skincare, and eye drops. It has a significant market presence in Asia and Europe, bolstered by its recent consolidation of Eu Yan Sang International Ltd. in Singapore and Mono chem-pharm Produkte GmbH in Austria.
YTD Price Performance: -10.18%
Average Trading Volume: 5,490
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $3.72B
For a thorough assessment of 4527 stock, go to TipRanks’ Stock Analysis page.